Acute DNA damage activates the tumour suppressor p53 to promote radiation-induced lymphoma

Nature Communications

Volumn 6, Issue , 2015, Pages

  Lee, Chang Lung ^a   Castle, Katherine D ^a   Moding, Everett J ^a   Blum, Jordan M ^a   Williams, Nerissa ^a   Luo, Lixia ^a   Ma, Yan ^a   Borst, Luke B ^b   Kim, Yongbaek ^c   Kirsch, David G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CD4 ANTIGEN; K RAS PROTEIN; MESSENGER RNA; PROTEIN P53; SHORT HAIRPIN RNA; T LYMPHOCYTE RECEPTOR BETA CHAIN; KRAS2 PROTEIN, MOUSE; PROTEIN P21; SMALL INTERFERING RNA;

CANCER; CARCINOGEN; DNA; GENE EXPRESSION; HEMATOLOGY; TOXICITY; TUMOR;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL EXPANSION; CHIMERA; CONTROLLED STUDY; DNA DAMAGE; FLOW CYTOMETRY; LONG TERM SURVIVAL; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; RADIATION CARCINOGENESIS; RADIATION INDUCED LYMPHOMA; RADIATION INDUCED NEOPLASM; THYMOCYTE; THYMUS LYMPHOMA; WHOLE BODY RADIATION; ADVERSE EFFECTS; ANIMAL; BONE MARROW TRANSPLANTATION; GENETICS; HEMATOPOIETIC STEM CELL; IMMUNOBLOTTING; LYMPHOMA; METABOLISM; NEOPLASMS, RADIATION-INDUCED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

MUS;

ANIMALS; BONE MARROW TRANSPLANTATION; DNA DAMAGE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; IMMUNOBLOTTING; LYMPHOMA; MICE; NEOPLASMS, RADIATION-INDUCED; PROTO-ONCOGENE PROTEINS P21(RAS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; THYMOCYTES; TUMOR SUPPRESSOR PROTEIN P53; WHOLE-BODY IRRADIATION;

EID: 84942163716     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9477     Document Type: Article

References (58)

1. Delaney, G., Jacob, S., Featherstone, C. & Barton, M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidencebased clinical guidelines. Cancer 104, 1129-1137 (2005).
2. Pant, V., Quintas-Cardama, A. & Lozano, G. The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood 120, 5118-5127 (2012).
3. Gudkov, A. V. & Komarova, E. A. Pathologies associated with the p53 response. Cold Spring Harb. Perspect. Biol. 2, a001180 (2010).
4. Gudkov, A. V. & Komarova, E. A. The role of p53 in determining sensitivity to radiotherapy. Nat. Rev. Cancer 3, 117-129 (2003).
5. Lee, C. L., Blum, J. M. & Kirsch, D. G. Role of p53 in regulating tissue response to radiation by mechanisms independent of apoptosis. Transl. Cancer Res. 2, 412-421 (2013).
6. Moding, E. J., Kastan, M. B. & Kirsch, D. G. Strategies for optimizing the response of cancer and normal tissues to radiation. Nat. Rev. Drug Discov. 12, 526-542 (2013).
7. Leonova, K. I. et al. A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in mice. Cell Cycle 9, 1434-1443 (2010).
8. Su, H., Ganapathy, S., Li, X., Yuan, Z. M. & Ha, C. S. p53-based strategy for protection of bone marrow from Y-90 Ibritumomab Tiuxetan. Int. J. Radiat. Oncol. Biol. Phys. 92, 1116-1122 (2015).
9. Kemp, C. J., Wheldon, T. & Balmain, A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat. Genet. 8, 66-69 (1994).
10. Lee, J. M., Abrahamson, J. L., Kandel, R., Donehower, L. A. & Bernstein, A. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene 9, 3731-3736 (1994).
11. Armstrong, G. T. et al. Late mortality among 5-year survivors of childhood cancer: A summary from the Childhood Cancer Survivor Study. J. Clin. Oncol. 27, 2328-2338 (2009).
12. Smith, S. M. et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 102, 43-52 (2003).
13. Newhauser, W. D. & Durante, M. Assessing the risk of second malignancies after modern radiotherapy. Nat. Rev. Cancer 11, 438-448 (2011).
14. Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B. & Evan, G. I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443, 214-217 (2006).
15. Hinkal, G., Parikh, N. & Donehower, L. A. Timed somatic deletion of p53 in mice reveals age-Associated differences in tumor progression. PLoS ONE 4, e6654 (2009).
16. Tomasetti, C. & Vogelstein, B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347, 78-81 (2015).
17. Dickins, R. A. et al. Tissue-specific and reversible RNA interference in transgenic mice. Nat. Genet. 39, 914-921 (2007).
18. Sarin, K. Y. et al. Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 436, 1048-1052 (2005).
19. Iwasaki, H. & Akashi, K. Hematopoietic developmental pathways: on cellular basis. Oncogene 26, 6687-6696 (2007).
20. Plett, P. A. et al. Establishing a murine model of the hematopoietic syndrome of the acute radiation syndrome. Health Phys. 103, 343-355 (2012).
21. Kaplan, H. S. & Brown, M. B. A quantitative dose-response study of lymphoidtumor development in irradiated C 57 black mice. J. Natl Cancer Inst. 13, 185-208 (1952).
22. Demarest, R. M., Ratti, F. & Capobianco, A. J. Its T-ALL about Notch. Oncogene 27, 5082-5091 (2008).
23. Martins, V. C. et al. Cell competition is a tumour suppressor mechanism in the thymus. Nature 509, 465-470 (2014).
24. Beverly, L. J., Felsher, D. W. & Capobianco, A. J. Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression. Cancer Res. 65, 7159-7168 (2005).
25. Fleenor, C. J., Marusyk, A. & DeGregori, J. Ionizing radiation and hematopoietic malignancies: Altering the adaptive landscape. Cell Cycle 9, 3005-3011 (2010).
26. Johnson, L. et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111-1116 (2001).
27. Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665 (2007).
28. Martins, C. P., Brown-Swigart, L. & Evan, G. I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323-1334 (2006).
29. Michalak, E. M. et al. Apoptosis-promoted tumorigenesis: gamma-irradiationinduced thymic lymphomagenesis requires Puma-driven leukocyte death. Genes Dev. 24, 1608-1613 (2010).
30. Labi, V. et al. Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation. Genes Dev. 24, 1602-1607 (2010).
31. Kaplan, H. S. & Brown, M. B. Development of lymphoid tumors in nonirradiated thymic grafts in thymectomized irradiated mice. Science 119, 439-440 (1954).
32. Kaplan, H. S. & Brown, M. B. Protection against radiation-induced lymphoma development by shielding and partial-body irradiation of mice. Cancer Res. 12, 441-444 (1952).
33. Kaplan, H. S., Brown, M. B. & Paull, J. Influence of bone-marrow injections on involution and neoplasia of mouse thymus after systemic irradiation. J. Natl Cancer Inst. 14, 303-316 (1953).
34. Kaplan, H. S., Moses, L. E., Brown, M. B., Nagareda, C. S. & Hirsch, B. B. The time factor in inhibition of lymphoid-Tumor development by injection of marrow cell suspensions into irradiated C57BL mice. J. Natl Cancer Inst. 15, 975-979 (1955).
35. Kiel, M. J., Yilmaz, O. H., Iwashita, T., Terhorst, C. & Morrison, S. J. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121, 1109-1121 (2005).
36. Simonnet, A. J. et al. Phenotypic and functional changes induced in hematopoietic stem/progenitor cells after gamma-ray radiation exposure. Stem Cells 27, 1400-1409 (2009).
37. Kent, D. G. et al. Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. Blood 113, 6342-6350 (2009).
38. Vazquez, S. E., Inlay, M. A. & Serwold, T. CD201 and CD27 identify hematopoietic stem and progenitor cells across multiple murine strains independently of Kit and Sca-1. Exp. Hematol. 43, 578-585 (2015).
39. Bondar, T. & Medzhitov, R. p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell 6, 309-322 (2010).
40. Brady, C. A. et al. Distinct p53 transcriptional programs dictate acute DNAdamage responses and tumor suppression. Cell 145, 571-583 (2011).
41. Li, T. et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149, 1269-1283 (2012).
42. Bieging, K. T., Mello, S. S. & Attardi, L. D. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 14, 359-370 (2014).
43. Marusyk, A., Porter, C. C., Zaberezhnyy, V. & DeGregori, J. Irradiation selects for p53-deficient hematopoietic progenitors. PLoS Biol. 8, e1000324 (2010).
44. Marusyk, A. et al. Irradiation alters selection for oncogenic mutations in hematopoietic progenitors. Cancer Res. 69, 7262-7269 (2009).
45. Kaplan, H. S., Carnes, W. H., Brown, M. B. & Hirsch, B. B. Indirect induction of lymphomas in irradiated mice. I. Tumor incidence and morphology in mice bearing nonirradiated thymic grafts. Cancer Res. 16, 422-425 (1956).
46. Wong, T. N. et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518, 552-555 (2015).
47. Lee, C. L., Lento, W. E., Castle, K. D., Chao, N. J. & Kirsch, D. G. Inhibiting glycogen synthase kinase-3 mitigates the hematopoietic acute radiation syndrome in mice. Radiat. Res. 181, 445-451 (2014).
48. Jacks, T. et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1-7 (1994).
49. Kunder, S. et al. A comprehensive antibody panel for immunohistochemical analysis of formalin-fixed, paraffin-embedded hematopoietic neoplasms of mice: Analysis of mouse specific and human antibodies cross-reactive with murine tissue. Toxicol. Pathol. 35, 366-375 (2007).
50. Dodd, R. D. et al. NF1 deletion generates multiple subtypes of soft-Tissue sarcoma that respond to MEK inhibition. Mol. Cancer Ther. 12, 1906-1917 (2013).
51. Jackson, E. L. et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65, 10280-10288 (2005).
52. ONeil, J. et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med. 204, 1813-1824 (2007).
53. Zhang, H., Saitoh, H. & Matunis, M. J. Enzymes of the SUMO modification pathway localize to filaments of the nuclear pore complex. Mol. Cell. Biol. 22, 6498-6508 (2002).
54. Bertwistle, D., Zindy, F., Sherr, C. J. & Roussel, M. F. Monoclonal antibodies to the mouse p19(Arf) tumor suppressor protein. Hybrid. Hybridomics 23, 293-300 (2004).
55. Lim, D. S. et al. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 404, 613-617 (2000).
56. Dickins, R. A. et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 37, 1289-1295 (2005).
57. Milbury, C. A. et al. Determining lower limits of detection of digital PCR assays for cancer-related gene mutations. Biomol. Detect. Quantif. 1, 8-22 (2014).
58. McCulloch, E. A. in Methods in Molecular Medicine Vol. 63, 153-160 (2001).